# Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

> **NCT00913913** · PHASE2 · TERMINATED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 8 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** DC vaccine
- **DRUG:** Bevacizumab
- **BIOLOGICAL:** IL-2
- **BIOLOGICAL:** IFN

## Key facts

- **NCT ID:** NCT00913913
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** low accrual not allowing site to meeting statistical endpoints
- **Last updated:** 2015-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913913, "Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00913913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*